Prognica Labs

Accelerating
Drug Discovery
with AI

Prognica Labs fuses frontier AI with deep biological expertise to compress the drug discovery timeline from decades to years – enabling the next generation of life-saving therapeutics.

Full-Spectrum AI Drug Discovery

From first target to lead candidate, modular or end-to-end.

Target Discovery & Validation

AI-driven multi-omics analysis identifies and validates high-confidence drug targets 3× faster than conventional approaches.

Generative Hit Identification

Generative chemistry models propose novel hit compounds with optimized binding profiles from vast chemical space.

Lead Optimization (SAR)

AI-guided structure-activity relationship modeling accelerates lead optimization with precision ADMET predictions.

ADMET & Safety Prediction

Predictive safety models with >85% accuracy reduce late-stage attrition and de-risk clinical translation.

Biomarker Intelligence

Patient stratification and biomarker identification powered by genomic and proteomic AI for precision trials.

End-to-End CRO Partnership

Fully integrated research organization offering risk-sharing, milestone-based, and fee-for-service models.

Why Prognica Labs

The AI Advantage in
Drug Discovery

Traditional drug discovery is slow, expensive, and failure-prone. Prognica Labs reimagines every step with AI, cutting timelines and costs while improving probability of success.

Explainable AI

Every prediction comes with mechanistic rationale, critical for regulatory submissions and scientific confidence.

Modular + End-to-End

Plug in at any stage or engage us for the full discovery journey. Flexible to your existing workflows.

Risk-Sharing Models

We align incentives through milestone and co-development agreements, we succeed when you succeed.

Regulatory Ready

AI documentation, audit trails, and explainability outputs designed for IND and regulatory submissions.

Awards & Recognitions

Honors reflecting our
Mission & Impact

In News & Media

Making waves in the
Global Media